IMRN
Immuron Ltd (IMRN)
Healthcare • NASDAQ • $0.94-3.98%
- Symbol
- IMRN
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.94
- Daily Change
- -3.98%
- Market Cap
- $7.93M
- Trailing P/E
- N/A
- Forward P/E
- -98.21
- 52W High
- $2.35
- 52W Low
- $0.68
- Analyst Target
- $3.90
- Dividend Yield
- 0.00%
- Beta
- 0.47
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; ProIBS, an over the counter orally administered product containing the proprietary ingredient AVH200 for the treatment of irritable bowel syndrome; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops IM…
Company websiteResearch IMRN on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.